The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: a systematic review and meta-analysis.

CONCLUSION: Our meta-analysis suggests that the survival benefits of EGFR inhibitors might depend on primary sites in HNSCC. Further studies are needed to confirm this finding.
PMID: 33587969 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - February 12, 2021 Category: Radiology Authors: Nie D, Wang X, Sun M, Feng Z, Pei F, Liu W, Wang Z, Han F Tags: Radiother Oncol Source Type: research